Castle Biosciences (CSTL) stock price, revenue, and financials

Castle Biosciences annual revenue was $22.79 m in FY 2018

$8.7 M

Castle Biosciences Revenue Q1, 2019
Castle Biosciences Gross profit (Q1, 2019)7.1 M
Castle Biosciences Gross profit margin (Q1, 2019), %81.7%
Castle Biosciences Net income (Q1, 2019)-1.4 M
Castle Biosciences EBIT (Q1, 2019)-321.4 K
Castle Biosciences Cash, 31-Mar-201916.2 M

Castle Biosciences Revenue

Castle Biosciences revenue was $22.79 m in FY, 2018 which is a 65.7% year over year increase from the previous period.

Embed Graph

Castle Biosciences Income Statement

Annual

USDFY, 2017FY, 2018

Revenue

13.8m22.8m

Revenue growth, %

66%

Cost of goods sold

4.9m5.3m

Gross profit

8.8m17.5m

Gross profit Margin, %

64%77%

R&D expense

4.5m4.9m

General and administrative expense

15.3m16.5m

Operating expense total

19.7m21.3m

EBIT

(10.9m)(3.8m)

EBIT margin, %

(79%)(17%)

Interest expense

1.6m2.3m

Interest income

26.2k23.5k

Pre tax profit

(12.4m)(6.4m)

Income tax expense

9.7k8.6k

Net Income

(12.4m)(6.4m)

Quarterly

USDQ1, 2018Q1, 2019

Revenue

3.7m8.7m

Cost of goods sold

1.3m1.6m

Gross profit

2.4m7.1m

Gross profit Margin, %

66%82%

R&D expense

1.3m1.4m

General and administrative expense

4.2m6.0m

Operating expense total

5.5m7.4m

EBIT

(3.1m)(321.4k)

EBIT margin, %

(84%)(4%)

Interest expense

530.2k1.0m

Interest income

5.4k20.8k

Pre tax profit

(3.6m)(1.4m)

Net Income

(3.6m)(1.4m)

Castle Biosciences Balance Sheet

Annual

USDFY, 2017FY, 2018

Cash

1.2m4.5m

Accounts Receivable

4.7m12.1m

Prepaid Expenses

515.5k675.6k

Inventories

304.6k882.2k

Current Assets

6.7m18.1m

PP&E

1.5m1.5m

Total Assets

9.8m22.4m

Accounts Payable

1.1m1.5m

Short-term debt

1.0m

Current Liabilities

5.2m6.7m

Long-term debt

17.6m24.5m

Total Debt

18.6m24.5m

Total Liabilities

24.1m32.5m

Common Stock

2.3k2.3k

Preferred Stock

36.0m46.5m

Additional Paid-in Capital

808.8k920.9k

Retained Earnings

(51.1m)(57.5m)

Total Equity

(14.3m)(10.1m)

Debt to Equity Ratio

-1.3 x-2.4 x

Debt to Assets Ratio

1.9 x1.1 x

Financial Leverage

-0.7 x-2.2 x

Quarterly

USDQ1, 2019

Cash

16.2m

Accounts Receivable

9.2m

Prepaid Expenses

741.4k

Inventories

809.3k

Current Assets

27.0m

PP&E

1.7m

Total Assets

31.0m

Accounts Payable

1.6m

Short-term debt

3.6m

Current Liabilities

9.0m

Long-term debt

23.6m

Total Debt

27.2m

Total Liabilities

33.8m

Common Stock

2.3k

Preferred Stock

46.6m

Additional Paid-in Capital

9.4m

Retained Earnings

(58.8m)

Total Equity

(2.9m)

Financial Leverage

-10.7 x

Castle Biosciences Cash Flow

Annual

USDFY, 2017FY, 2018

Net Income

(12.4m)(6.4m)

Depreciation and Amortization

270.3k287.1k

Accounts Receivable

(428.2k)(8.4m)

Inventories

(115.6k)(577.7k)

Accounts Payable

370.9k197.2k

Cash From Operating Activities

(12.2m)(12.3m)

Purchases of PP&E

(494.9k)(277.0k)

Cash From Investing Activities

(494.9k)(277.0k)

Long-term Borrowings

(2.0m)

Cash From Financing Activities

8.9m15.8m

Net Change in Cash

(3.9m)3.3m

Interest Paid

1.1m1.6m

Income Taxes Paid

159.7k

Quarterly

USDQ1, 2019Q1, 2020

Net Income

(3.6m)(1.4m)

Depreciation and Amortization

70.4k77.4k

Accounts Receivable

(38.0k)3.8m

Inventories

97.0k97.0k

Accounts Payable

(217.2k)(328.8k)

Cash From Operating Activities

(2.5m)1.3m

Purchases of PP&E

(28.6k)(243.6k)

Cash From Investing Activities

(28.6k)(243.6k)

Long-term Borrowings

(989.1k)

Cash From Financing Activities

5.3m10.7m

Net Change in Cash

2.8m11.8m

Interest Paid

453.5k572.4k

Income Taxes Paid

(150.0k)

Castle Biosciences Ratios

USDY, 2019

EV/EBIT

-1.2 k x

EV/CFO

302.2 x

Revenue/Employee

112.2k

Financial Leverage

-10.7 x

Castle Biosciences Operating Metrics

Q1, 2019

Clinical Samples Processed to Date

40 k